FDA warns 3D Imaging of CGMP failures in sterile PET drug manufacturing and outdated drug listings.
What happened
FDA inspected 3D Imaging's Little Rock facility from June 9 to 13, 2025, and found aseptic connections made in an open benchtop area, a hot cell in poor repair, inadequate environmental monitoring, exposed operator skin and hair during manufacturing, and poor sterility testing technique. FDA also reviewed the firm's drug listing submissions and found that Fludeoxyglucose F18 was not updated or certified as required.
What FDA found
The facility was not adequate to prevent contamination, including aseptic connections in an open benchtop area and rust and residue in the hot cell near where sterile product is filtered into vials.
21 CFR 212.30(a) and (b)Environmental monitoring was inadequate because the hot cell where FDG is filtered into final vials was not monitored and the alert and action levels were not appropriate.
21 CFR 212.30(a) and (b)Production and process controls were inadequate because operators had exposed skin and hair during manufacturing and two operators had not been requalified by media fill at least annually.
21 CFR 212.50Laboratory methods were inadequate because sterility testing was performed with poor aseptic technique and test tubes were shaken before reading, which may mask results.
21 CFR 212.60The drug listing for Fludeoxyglucose F18 was not updated or certified as required.
section 510(j) of the FD&C Act (21 U.S.C. 360(j)) and 21 CFR part 207The drug listings for Ammonia N 13 and Sodium Fluoride F-18 also had not been updated or certified.
section 510(j) of the FD&C Act (21 U.S.C. 360(j)) and 21 CFR part 207
What FDA wants
FDA asks the company to respond in writing within 15 working days, correct the violations promptly, and provide detailed remediation plans and updated drug listings.
Who should pay attention
- hospitals and imaging centers that use PET drugs
- PET drug manufacturers and aseptic processing operators
- distributors and prescribers of FDG and other PET radiopharmaceuticals
This is a summary. Read the original letter on fda.gov.